Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Funding Agency
For Profit
(FP)
766.7M Funding
668 People
1745 Grants
People
Conrad Clemens
Health Promotion Sciences
Senior Associate Dean
Abhijeet Kumar
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Sasha Taleban
Medicine
Associate Professor
Franz Rischard
Medicine
Professor
VENKATESH KUMAR ARIYAMUTHU
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Klearchos Papas
Surgery
Professor
Rachna Shroff
Medicine
Professor
Cori Daines
Pediatrics
Professor
Elena Young
COM - Phoenix Internal Medicine
Research Compliance Manager II
Alejandro Recio Boiles
Medicine
Assistant Professor, Medicine - (Clinical Scholar Track)
Recent Grants
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom
Active
·
2024
·
$978K
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have
Active
·
2024
·
$964K
Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
Active
·
2024
·
$822.1K
A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Active
·
2024
·
$502.8K
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Track Adenoc
Active
·
2024
·
$462K
Protocol Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)
Active
·
2024
·
$370.5K
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for
Active
·
2024
·
$345.7K
A Registry Study for Subjects who Participated in AMBULATE DFU and AMBULATE DFU II.
Active
·
2024
·
$224.8K
TEP Renewable Power Forecasting
Active
·
2024
·
$120K
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck S
Active
·
2024
·
$119.8K